logo-loader
viewBritvic PLC

Britvic mulls over bottling facilities sale

The J2O producer would give up three juice manufacturing sites in France, its related private label juice business and the Fruité brand for an undisclosed price

Britvic PLC - J2O’s producer Britvic mulls over bottling facilities sale
The company also has exclusive agreements with PepsiCo for UK and Ireland distribution of Pepsi and 7UP

Britvic PLC (LON:BVIC) has entered talks with Dutch group Refresco, the world’s largest independent bottler, over the potential sale of facilities located in France.

The FTSE 250-listed producer of J2O and Tango would give up three juice manufacturing sites in France, its related private label juice business and the Fruité brand while retaining ownership of the Pressade and Fruit Shoot brands, which Refresco would produce as part of the agreement.

READ: Britvic on track in spite of domestic challenges

The company, which has exclusive agreements with PepsiCo Inc. (NASDAQ:PEP) for UK and Ireland distribution of Pepsi and 7UP, is keeping the site in Crolles, located near Lyon, where it produces the Teisseire and Moulin De Valdonne brands and private label syrups.

The transaction, scheduled to complete in spring 2020, is expected to result in a “modest impact” on adjusted underlying earnings.

“We see this as further confirmation that France has been a disappointment this second half of 2019 and that Britvic are taking steps to remedy the circumstances by selling off bits that are more capital intensive,” analysts at Liberum said in a note.

“Without a value, it's hard to judge the merits of such a deal but it looks like a sensible decision.”

Shares in Britvic were little changed on the news.

Quick facts: Britvic PLC

Price: 815.5 GBX

LSE:BVIC
Market: LSE
Market Cap: £2.18 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Amryt Pharma releases Q-2 financials that show strong revenue growth as...

Amryt Pharma (Nasdaq: AMYT) CEO Dr Joe Wiley joined Steve Darling from Proactive with news the company saw a nice increase in revenue as they released their Q-2 numbers. Dr Wiley talked about some of the numbers and what was driving that revenue. Wiley also told Proactive the company has, for...

34 minutes ago

2 min read